Hodgkin's disease and non-Hodgkin's lymphoma

Current Opinion in Hematology

Volumn 6, Issue 4, 1999, Pages 205-215

  Gregory Bociek, R ^a   Armitage, James O ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BLEOMYCIN; CHLORMETHINE; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; FOLINIC ACID; METHOTREXATE; PREDNISONE; PURINE DERIVATIVE; RITUXIMAB; VINBLASTINE; VINCRISTINE;

ADVANCED CANCER; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; DRUG EFFICACY; DRUG MEGADOSE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HODGKIN DISEASE; HUMAN; MULTIMODALITY CANCER THERAPY; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RECURRENT CANCER; REVIEW; TREATMENT INDICATION; TREATMENT OUTCOME;

HODGKIN DISEASE; HUMANS; LYMPHOMA, NON-HODGKIN;

EID: 0032797032     PISSN: 10656251     EISSN: None     Source Type: Journal    
DOI: 10.1097/00062752-199907000-00003     Document Type: Review

References (126)

1. Landis SH, Murray T, Bolden S, Wingo PA: Cancer Statistics, 1999. CA Cancer J Clin 1999, 49:8-31.
2. Devasa SS, Blot WJ, Stone BJ, Miller BA, Tarone RE, Fraumani JF Jr: Recent cancer trends in the United States. J Natl Cancer Inst 1995, 87:175-182.
3. Greiner TC, Medeiros LJ, Jaffe ES: Non-Hodgkin's lymphoma. Cancer 1995, 75:370-380.
4. Burkitt DP: A sarcoma involving the jaws in African children. Br J Surg 1958, 46:218-223.
5. Knowles DM, Cesarman E, Chadburn A, Frizzera G, Chen J, Rose EA, Michler RE: Correlative morphologic and molecular genetic analysis demonstrates three distinct categories of posttransplantation lymphoproliferative disorders. Blood 1995, 85:552-565.
6. Ho M, Miller G, Atchison RW, Breinig MK, Dummer JS, Andiman W, et al.: Epstein-Barr virus infections and DNA hybridization studies in posttransplantation lymphoma and lymphoproliferative lesions: the role of primary infection. J Infect Dis 1985, 152:876-886.
7. Chang Y, Cesarman E, Culpepper J, Knowles DM, Moore PS: Identification of herpes-like DNA in AIDS-associated Kaposi's sarcoma. Science 1994, 266:1865-1869.
8. Nador RG, Cesarman E, Dawson DB, Ansari MQ, Said J, Knowles DM: Primary effusion lymphoma: a distinct clinicopathologic entity associated with the Kaposi's sarcoma-associated Herpes virus. Blood 1996, 88:645-656.
9. Soulier J, Grollet L, Oksenhendler E, Cacoub P, Cazals-Hatem D, Babinet P, et al.: Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease. Blood 1995, 86:1276-1280.
10. Harris NL, Jaffe ES, Stein H, Banks PM, Chan JKC, Cleary ML, et al.: A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994, 84:1361-1392.
11. The Non-Hodgkin's Lymphoma Classification Project: A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. Blond 1997, 89:3909-3918.
12. The International Non-Hodgkin's Lymphoma Prognostic Factors Project: A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993, 329:987-994.
13. Armitage JO, Weisenburger DD for the Non-Hodgkin's Lymphoma Classification Project: New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. J Clin Oncol 1998, 16:2780-2795. This review of the histologic and clinical features of the most common non-Hodgkin's lymphomas emphasizes the applicability of the International Prognostic Index.
14. Horning SJ, Rosenberg SA: The natural history of initially untreated low-grade non-Hodgkin's lymphomas. N Engl J Med 1984, 311:1471-1475.
15. Gospodarowicz MK, Bush RS, Brown TC, Chua T: Prognostic factors in nodular lymphomas: a multivariate analysis based on the Princess Margaret Hospital experience. Int J Radiat Oncol Biol Phys 1984, 10:489-497.
16. Landberg TG, Hakansson LG, Moller TR, Mattsson WKI, Landys KE, Johansson BG, et al.: CVP-remission-maintenance in stage I or II non-Hodgkin's lymphomas. Cancer 1979, 44:831-838.
17. McLaughlin P, Fuller LM, Velasquez WS, Sullivan-Halley JA, Butler JJ, Cabanillas F: Stage I-II follicular lymphoma. Treatment results for 76 patients. Cancer 1986, 58:1596-1602.
18. Monfardini S, Banfi A, Bonadonna G, Rilke F, Milani F, Valagussa P, Lattuada A: Improved five year survival after combined radiotherapy-chemotherapy for stage I-II non-Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys 1980, 6:125-134.
19. Toonkel LM, Fuller LM, Gamble JF, Butler JJ, Martin RG, Shullenberger CC: Laparotomy staged I and II non-Hodgkin's lymphomas. Cancer 1980, 45:249-260.
20. Portlock CS, Fischer DS, Cadman E, Lundberg WB, Levy A, Bobrow S, et al.: High-dose pulse chlorambucil in advanced, low-grade non-Hodgkin's lymphoma. Cancer Treat Rep 1987, 71:1029-1031.
21. Kimby E, Bjorkholm M, Gahrton G, Glimelius B, Hagberg H, Johansson B, et al.: Chlorambucil/prednisone vs. CHOP in symptomatic low-grade non-Hodgkin's lymphomas: a randomized trial from the Lymphoma Group of Central Sweden. Ann Oncol 1994, 5:67-71.
22. Bagley CM Jr, Devita VT Sr, Berard CW, Canellos GP: Advanced lymphosarcoma: intensive cyclical combination chemotherapy with cyclophosphamide, vincristine and prednisone. Ann Intern Med 1972, 76:227-234.
23. Chisesi T, Congiu M, Contu A, Coser P, Moretti L, Porcellini A, et al.: Randomized study of chlorambucil compared to interferon (alfa-2b) combined with chlorambucil in low-grade non-Hodgkin's lymphoma: an interim report of a randomized study. Eur J Cancer 1991, 27:31-33.
24. Price CG, Rohatiner AZ, Steward W, Deakin D, Bailey N, Norton A, et al.: Interferon-alpha 2b in the treatment of follicular lymphoma: preliminary results of a trial in progress. Ann Oncol 1991, 2:141-145.
25. Solal-Celigny P, Lepage E, Brousse N, Reyes F, Haioun C, Leporrier M, et al.: Recombinant interferon alfa-2b combined with a regimen containing doxorubicin in patients with advanced follicular lymphoma. N Engl J Med 1993, 329:1608-1614.
26. Smalley RV, Andersen JW, Hawkins MJ, Bhide V, O'Connell MJ, Oken M, Borden EC: Interferon alfa combined with cytotoxic chemotherapy for patients with non-Hodgkin's lymphoma. N Engl J Med 1992, 327:1336-1341.
27. Hagenbeek A, Carde P, Meerwaldt JH, Somers R, Thomas J, De Bock R, et al.: Maintenance of remission with human recombinant interferon alfa-2a in patients with stages III and IV low-grade malignant non-Hodgkin's lymphoma. J Clin Oncol 1998, 16:41-47.
28. Arranz R, Garcia-Alfonso P, Sobrina P, Zamora P, Carrion R, Garcia-Larana J, et al.: Role of interferon alfa-2b in the induction and maintenance treatment of low-grade non-Hodgkin's lymphoma: results from a prospective, multicenter trial with double randomization. J Clin Oncol 1998, 16:1538-1546. The authors of this two-phase randomized trial compared CVP (cyclophosphamide, vincristine, and prednisone) with CVP plus interferon. The first phase of the trial showed a significant increase in duration of response and progression-free survival for patients receiving CVP plus interferon during induction. In the second phase of the trial, responders were randomly assigned to receive maintenance interferon therapy or no further therapy. No difference was seen in the duration of response between these two groups, and this was independent of the treatment received in the first phase of the study.
29. Aviles A, Duque G, Talavera A, Guzman R: Interferon alpha 2b as maintenance therapy in low grade malignant lymphoma improves duration of remission and survival. Leuk Lymphoma 1996, 20:495-499.
30. Cole BF, Solal-Celigny P, Gelber RD, Lepage E, Gisselbrecht C, Reyes F, et al.: Quality-of-life - adjusted survival analysis of interferon alfa-2b treatment for advanced follicular lymphoma: an aid to clinical decision making. J Clin Oncol 1998, 16:2339-2344. This survival analysis, adjusted for quality of life in patients with advanced follicular lymphoma (GELF 86 randomized trial), shows that chemotherapy plus interferon provided a greater amount of quality-adjusted survival for most patients compared to those receiving chemotherapy only.
31. Falkson CI: Fludarabine: a phase II trial in patients with previously treated low-grade lymphoma. Am J Clin Oncol 1996, 19:268-270.
32. Caracciolo F, Capochiani E, Papineschi F, Petrini M: A new effective treatment for indolent lymphoma: a pilot study with fludarabine, idarubicin and prednisone combination (FLIDA). Hematol Oncol 1997, 15:27-31.
33. Zinzani PL, Bendandi M, Magagnoli M, Gherlinzoni F, Merla E, Tura S: Fludarabine-mitoxantrone combination-containing regimen in recurrent low-grade non-Hodgkin's lymphoma. Ann Oncol 1997, 8:379-383.
34. Zinzani PL, Bendandi M, Magagnoli M, Rondelli D, de Vivo A, Benni M, et al.: Results of a fludarabine induction and alpha-interferon maintenance protocol in pretreated patients with chronic lymphocytic leukemia and low-grade non-Hodgkin's lymphoma. Eur J Haematol 1997, 59:82-88.
35. Wahl RL, Zasadny KR, MacFarlane D, Francis IR, Ross CW, Estes J, et al.: Iodine-131 anti-B1 antibody for B-cell lymphoma: an update on the Michigan Phase I experience. J Nuclear Med 1998, 39(suppl):21-27.
36. Lundin J, Osterborg A, Brittinger G, Crowther D, Dombret H, Engert A, et al.: CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H treatment in low-grade non-Hodgkin's lymphoma. J Clin Oncol 1998, 16:3257-3263.
37. Anderson KC, Bates MP, Slaughenhoupt BL, Pinkus GS, Schlossman SF, Nadler LM: Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation. Blood 1984, 63:1424-1433.
38. Press OW, Appelbaum F, Ledbetter JA, Martin PJ, Zarling J, Kidd P, Thomas ED: Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas. Blood 1987, 69:584-591.
39. Einfeld DA, Brown JP, Valentine MA, Clark EA, Ledbetter JA: Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains. EMBO J 1988, 7:711-717.
40. Reff ME, Camer K, Chambers KS, Chinn PC, Leonard JE, Rabb R, et al.: Depletion of B cells in vivo by a chimeric mouse numan monoclonal antibody to CD20. Blood 1994, 83:435-445.
41. Taji H, Kagami Y, Okada Y, Andou M, Nishi Y, Saito H, et al.: Growth inhibition of CD2-positive B lymphoma cell lines by IDEC-C2B6 anti-CD20 monoclonal antibody. Jpn J Cancer Res 1998, 89:748-756.
42. Golay JT, Clark EA, Beverley PC: The CD20 (Bp35) antigen is involved in activation of B cells from the G0 to the G1 phase of the cell cycle. J Immunol 1985, 135:3795-3801.
43. 2+ conductance found constitutively in B lymphocytes. J Cell Biol 1993, 121:1121-1132.
44. Maloney DG, Grillo-Lopez AJ, Bodkin DJ, White CA, Liles T-M, Royston I, et al.: IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol 1997, 15:3266-3274.
45. Maloney DG, Grillo-Lopez AJ, White CA, Bodkin D, Schilder RJ, Neidhart JA, et al.: IDEC-C2B8 (Rituximab) Anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997, 90:2188-2195.
46. 2 weekly for four weeks. Infusional side effects were most common with the initial infusion, and clinical responses were seen in 17 patients (46%). The median time to progression in patients who responded to therapy was 10.2 months.
47. Davis T, Levy R, White CA, Czuczman M, McLaughlin P, Link B, et al.: Rituximab: phase II retreatrnent study in patients with low-grade or follicular NHL [abstract]. Blood 1998, 92:414.
48. Jensen M, Winkler U, Manzke O, Diehl V, Engert A: Rapid tumor lysis in a patient with B-cell chronic lymphocytic leukemia and lymphocytosis treated with an anti-CD 20 monoclonal antibody (IDEC-C2B8, Rituximab). Ann Hematol 1998, 77:89-91. This is a case report of tumor lysis in a patient with chronic lymphocytic leukemia and peripheral lymphocytosis who received standard doses of rituximab.
49. Link BK, Grossbard ML, Fisher RI, Czuczman MS, Gilman P, Lowe AM, Vose JM: Phase II pilot study of the safety and efficacy of rituximab in combination with CHOP chemotherapy in patients with previously untreated intermediate- or high-grade NHL [abstract]. Proc ASCO 1998, 17:3.
50. 131I-anti-B1 in patients with non-Hodgkin's lymphoma resulted in responses in 86% of patients and was relatively well tolerated when given with autologous stem cell infusion. Late toxicity most often manifested as an increase in thyroid-stimulating hormone levels.
51. 131I-lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma. J Clin Oncol 1998, 16:3246-3256.
52. Wilson WH, Little R, Pearson D, Jaffe ES, Steinberg SM, Cheson BD, et al.: Phase II and dose-escalation with or without granulocyte colony-stimulating factor study of 9-Aminocamptothecin in relapsed and refractory lymphomas. J Clin Oncol 1998, 16:2345-2351.
53. Haas R, Murea S, Hohaus S, Goldschmidt H, Engenhart R, Wannenmacher M, Hunstein W: Myeloablative high-dose therapy with peripheral blood stem cell transplantation in patients with low-grade non-Hodgkin's lymphoma. In Autologous Marrow and Blood Transplantation, Proceedings of the 8th International Symposium. Edited by Dicke KA and Keating A. Charlottesville: Garden Jennings Publishing Company; 1997:167-176.
54. Bierman P, Vose J, Kollath J, Bishop M, Kessinger A, Armitage J: High-dose therapy followed by autologous hematopoietic rescue for follicular non-Hodgkin's lymphoma. In Autologous Marrow and Blood Transplantation. Proceedings of the 8th International Symposium. Edited by Dicke KA and Keating A. Charlottesville: Carden Jennings Publishing Company; 1997:157-166.
55. Freedman AS, Gribbon JG, Neuberg D, Mauch P, Soiffer RJ, Anderson KC, et al.: High-dose therapy and autologous bone marrow transplantation in patients with follicular lymphoma during first remission. Blood 1996, 88:2780-2786.
56. Hass R, Moos M, Mohle R, Dohner H, Witt B, Goldschmidt H, et al.: High-dose therapy with peripheral blood progenitor cell transplantation in low-grade non-Hodgkin's lymphoma. Bone Marrow Transplant 1996, 17:149-155.
57. van Besien K, Sobocinski KA, Rowlings PA, Murphy SC, Armitage JO, Bishop MR, et al.: Allogeneic bone marrow transplantation for low-grade lymphoma. Blood 1998, 92:1832-1836. In this observational study from the International Bone Marrow Transplant Registry of 113 patients treated with high-dose therapy and HLA-identical sibling bone marrow transplantation, the 3-year probability of disease-free survival was 49%. Most deaths were treatment related.
58. Mandigers CM, Raemaekers JM, Schattenberg AV, Roovers EA, Bogman MJ, van-der-Maazen RW, et al.: Allogeneic bone marrow transplantation with T-cell-depleted marrow grafts for patients with poor-risk relapsed low-grade non-Hodgkin's lymphoma. Br J Haematol 1998, 100:198-206.
59. Verdonck LF, Dekker AW, Lokhorst HM, Petersen EJ, Nieuwenhuis HK: Allogeneic versus autologous bone marrow transplantation for refractory and recurrent low-grade non-Hodgkin's lymphoma. Blood 1997, 90:4201-4205.
60. Kaminski MS, Coleman CN, Colby TV, Cox RS, Rosenberg SA: Factors predicting survival in adults with stage I and II large-cell lymphoma treated with primary radiation therapy. Ann Intern Med 1986, 104:747-756.
61. Longo DL, Glatstein E, Duffey PL, Ihde DC, Hubbard SM, Fisher RI, et al.: Treatment of localized aggressive lymphomas with combination chemotherapy followed by involved-field radiation therapy. J Clin Oncol 1989, 7:1295-1302.
62. Nissen NI, Ersboll J, Hansen HS, Walbom-Jorgensen S, Pedersen-Bjergaard J, Hansen MM, Rygard J: A randomized study of radiotherapy versus radiotherapy plus chemotherapy in stage I-II non-Hodgkin's lymphoma. Cancer 1983, 52:1-7.
63. Miller TP, Dahlberg S, Cassady JR, Adelstein DJ, Spier CM, Grogan TM, et al.: Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. N Engl J Med 1998, 339:21-26. This well-designed, randomized trial compared eight cycles of CHOP with three cycles of CHOP, followed by involved-field radiotherapy for patients with clinically localized aggressive (Working Formulation Groups D-J) non-Hodgkin's lymphoma. It showed improved progression-free survival (77% compared with 64%) and overall survival (82% compared with 72%) in patients randomly assigned to combined therapy.
64. Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, et al.: Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993, 328:1002-1006.
65. Verdonck LF, van Putten WLJ, Hagenbeek A, Schouten HC, Sonneveld P, van Imhoff GW, et al.: Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin's lymphoma. N Engl J Med 1995, 332:1045-1051.
66. Gianni AM, Bregni M, Siena S, Brambilla C, Di Nicola M, Lombardi F, et al.: High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. N Engl J Med 1997, 336:1290-1297.
67. Haioun C, Lepage E, Gisselbrecht C, Bastion Y, Coiffier B, Brice P, et al.: Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkin's lymphoma: updated results of the prospective study LNH87-2. J Clin Oncol 1997, 15:1131-1137.
68. Santini G, Salvagno L, Leoni P, Chisesi T, De Souza C, Sertoli MR, et al.: VACOP-B versus VACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's lymphoma Cooperative Study Group. J Clin Oncol 1998, 16:2796-2802. This randomized trial comparing VACOP-B (etoposide, doxorubicin, cyclophosphamide, vincristrine, prednisone, and bleomycin) with VACOP-B plus consolidative autologous bone marrow transplantation showed a trend toward improved outcomes for patients with intermediate-high risk and high risk at diagnosis, as assessed by the International Prognostic Index.
69. Philip T, Guglielmi C, Hagenbeek A, Somers R, van der Lelie H, Bron D, et al.: Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995, 333:1540-1545.
70. Blay J-Y, Gomez F, Sebban C, Bachelot T, Biron P, Guglielmi C, et al.: The international prognostic index correlates to survival in patients with aggressive lymphoma in relapse: analysis of the PARMA trial. Blood 1998, 92:3562-3568. The International Prognostic Index yielded prognostic information for patients in the conventional-therapy arm of the PARMA trial but not in the high-dose arm, where long-term survival seemed to be independent of risk score.
71. Guglielmi C, Gomez F, Philip T, Hagenbeek A, Martelli M, Sebban C, et al.: Time to relapse has prognostic value in patients with aggressive lymphoma enrolled onto the Parma trial. J Clin Oncol 1998, 16:3264-3269. Time to relapse (with a cutoff of 12 months) has prognostic value for overall and progression-free survival, independent of response or treatment after two cycles of DHAP (dexamethasone, cytarabine, and cisplatin) chemotherapy.
72. Coiffier B, Haioun C, Ketterer N, Engert A, Tilly H, Ma D, et al.: Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood 1998, 92:1927-1932.
73. Romokh R, Berger F, Delsol G, Charrin C, Bertheas M-F, Ffrench M, et al.: Rearrangement and overexpression of the BCL-1/PRAD-1 gene in intermediate lymphocytic lymphomas and in t(11q13)-bearing leukemias. Blood 1993, 81:3063-3067.
74. Samaha H, Dumontet C, Ketterer N, Moullet I, Thieblemeont C, Bouafia F, et al.: Mantle cell lymphoma: a retrospective study of 121 cases. Leukemia 1998, 12:1281-1287. This large, descriptive series of 121 patients with mantle cell lymphoma shows the prognostic significance of age, hemoglobin concentration, performance status, and peripheral blood involvement on this lymphoma.
75. Pott C, Tiemann M, Inke B, Ott MM, von-Hofen M, Bolz I, et al.: Structure of bcl-1 and IgH-CDR3 rearrangements as clonal markers in mantle cell lymphomas. Leukemia 1998, 12:1630-1637.
76. Delmer A, Ajchenbaum-Cymbalista F, Tang R, Redmond S, Faussat AM, Marie JP, Zittoun R: Over-expression of cyclin D1 in chronic B-cell malignancies with abnormality of chromosome 11q13. Br J Haematol 1995, 89:798-804.
77. Oinonen R, Franssila K, Teerenhovi L, Lappalainen K, Elonen E: Mantle cell lymphoma: clinical features, treatment and prognosis of 94 patients. Eur J Cancer 1998, 34:329-336.
78. Bosch F, Lopez-Guillermo A, Campo E, Ribera JM, Conde E, Piris MA, et al.: Mantle cell lymphoma: presenting features, response to therapy, and prognostic factors. Cancer 1998, 82:567-575.
79. Cohen PL, Kurtin PJ, Donovan KA, Hanson CA: Bone marrow and peripheral blood involvement in mantle cell lymphoma. Br J Haematol 1998, 101:302-310.
80. Kroger N, Hoffknecht M, Dreger P, Kruger W, Zeller W, Krull A, et al.: Long-term disease-free survival of patients with advanced mantle-cell lymphoma following high-dose chemotherapy. Bone Marrow Transplant 1998, 21:55-57.
81. Freedman AS, Neuberg D, Gribben JG, Mauch P, Soiffer RJ, Fisher DC, et al.: High-dose chemoradiotherapy and anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle-cell lymphoma: no evidence for long-term remission. J Clin Oncol 1998, 16:13-18. This study of 28 patients with chemosensitive mantle cell lymphoma who underwent high-dose therapy and purged autologous bone marrow transplantation estimates that 31% of patients will be disease-free at 4 years after this regimen. However, the lack of any evidence of a plateau suggests that cure may not be possible with autologous transplantation.
82. Adkins D, Brown R, Goodnough LT, Khoury H, Popovic W, DiPersio J: Case report: treatment of resistant mantle cell lymphoma with allogeneic bone marrow transplantation. Bone Marrow Transplant 1998, 21:97-99.
83. Blay J-Y, Sebban C, Surbiguet C, Ouachee M, Philip I, Philip T, Biron P: High-dose chemotherapy with hematopoietic stem cell transplantation in patients with mantle cell or diffuse centrocytic non-Hodgkin's lymphomas: a single center experience on 18 patients. Bone Marrow Transplant 1998, 21:51-54.
84. Khouri IF, Romaguera J, Kantarjian H, Palmer JL, Pugh WC, Korbling M, et al.: Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma. J Clin Oncol 1998, 16:3803-3809. In this study, an aggressive induction regimen induced a response rate of 93% in patients with mantle cell lymphoma. Previously untreated patients receiving this regimen had a better three-year event-free survival rate (72% compared with 28%), and a better overall survival rate (92% compared with 56%), than a historical control group receiving a CHOP-like induction regimen.
85. Andersen NS, Donovan JW, Borus JS, Poor CM, Neuberg D, Aster JC, et al.: Failure of immunologic purging in mantle cell lymphoma assessed by polymerase chain reaction detection of minimal residual disease. Blood 1997, 90:4212-4221.
86. Decaudin D, Bosq J, Tertian G, Nedellec G, Bennaceur A, Venuat A-M, et al.: Phase II trial of fludarabine monophosphate in patients with mantle-cell lymphomas. J Clin Oncol 1998, 16:579-583.
87. Kennedy BJ, Fregman AM, Menck HR: The national cancer data base report on Hodgkin's disease for 1985-1989 and 1990-1994. Cancer 1998, 83:1041-1047.
88. Kuppers R, Rajewsky K: The origin of Hodgkin and Reed/Sternberg cells in Hodgkin's disease. Annu Rev Immunol 1998, 16:471-493. This is a comprehensive review on the origin of Hodgkin's and Reed/Sternberg cells in Hodgkin's disease.
89. Izban KF, Nawrocki JF, Alkan S, Hsi ED: Monoclonal IgH gene rearrangement in microdissected nodules from nodular sclerosis Hodgkin's disease. Am J Clin Pathol 1998, 110:599-606.
90. Mikata A, Li DX, Kurosu K, Oda K, Yumoto N, Tamaru JI: Reappraisal of the relationship between immunoglobulin heavy chain gene rearrangement and Epstein-Barr virus infection in Reed-Sternberg cells of Hodgkin's disease. Leuk Lymphoma 1997, 28:145-152.
91. Secchiero P, Bonino LD, Lusso P, Abele MC, Reato G, Kerim S, et al.: Human herpesvirus type 7 in Hodgkin's disease. Br J Haamatol 1998, 101:492-499.
92. Kaplan HC: Role of intensive radiotherapy in the management of Hodgkin's disease. Cancer 1966, 19:356-367.
93. Liebenhaut MH, Hoppe RT, Efron B, Halpem J, Nelsen T, Rosenberg SA: Prognostic indicators of laparotomy findings in clinical stage I-II supradiaphragmatic Hodgkin's disease. J Clin Oncol 1989, 7:81-91.
94. Mauch P, Larson D, Osteen R, Silver B, Yeap B, Canellos G, et al.: Prognostic factors for positive surgical staging in patients with Hodgkin's disease. J Clin Oncol 1990, 8:257-265.
95. Hancock SL, Tucker MA, Hoppe RT: Factors affecting late mortality from heart disease after treatment of Hodgkin's disease. JAMA 1993, 270:1949-1955.
96. Hancock SL, Tucker MA, Hoppe RT: Breast cancer after treatment of Hodgkin's disease. J Natl Cancer Inst 1993, 85:25-31.
97. Salloum E, Doria R, Schubert W, Zelterman D, Holford T, Roberts KB, et al.: Second solid tumors in patients with Hodgkin's disease cured after radiation or chemotherapy plus adjuvant low-dose radiation. J Clin Oncol 1996, 14:2435-2443.
98. Nyandoto P, Muhonen T, Joensuu H: Second cancer among long-term survivors from Hodgkin's disease. Int J Radiat Oncol Biol Phys 1998, 42:373-378. In this large, retrospective review of 4020 person-years of follow-up after treatment for Hodgkin's disease, 77% of second cancers in patients were within or near previous radiation fields. The 20-year cumulative risk was 12% for developing a second cancer within a radiation field.
99. Devita VT Sr, Serpick A, Carbone PP: Combination chemotherapy in the treatment of advanced Hodgkin's disease. Ann Intern Med 1970, 73:881-895.
100. Specht L, Gray RG, Clarke MJ, Peto R, for the International Hodgkin's Disease Collaborative Group: Influence of more extensive radiotherapy and adjuvant chemotherapy on long-term outcome of early-stage Hodgkin's disease: a meta-analysis of 23 randomized trials involving 3,888 patients. J Clin Oncol 1998, 16:830-843. This large meta-analysis of patients from eight randomized trials of early-stage Hodgkin's disease showed a reduction in treatment failure but no demonstrable improvement in survival for patients receiving more extensive radiotherapy. Adding chemotherapy to radiotherapy halved the 10-year risk for failure.
101. Loeffler M, Brosteanu D, Hasenclever D, Sextro M, Assouline D, Bartolucci AA, et al., for the International Hodgkin's Disease Overview Study Group: Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin's disease. J Clin Oncol 1998, 16:818-829. This meta-analysis of 1740 patients with advanced Hodgkin's disease showed fewer deaths in patients who received chemotherapy, as compared with patients receiving combined modality therapy.
102. Aviles A., Delgado S.: A prospective clinical trial comparing chemotherapy, radiotherapy and combined therapy in the treatment of early stage Hodgkin's disease with bulky disease. Clin Lab Haematol 1998, 20:95-99. Patients who had bulky early-stage Hodgkin's disease were randomly assigned to either radiotherapy only, six cycles of ABVD only, or six cycles of ABVD with radiotherapy "sandwiched" between the third and fourth cycles. At 12 years, combined therapy produced superior disease-free and overall survival rates compared with either chemotherapy or radiotherapy alone.
103. Canellos GP, Anderson JR, Propert KJ, Nissen N, Cooper MR, Henderson ES, et al.: Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 1992, 327:1478-1484.
104. Bonadonna G, Valagussa P, Santoro A: Alternating non-cross-resistant combination chemotherapy with ABVD or MOPP in stage IV Hodgkin's disease: a report of eight year results. Ann Intern Med 1986, 104:739-746.
105. Longo DL, Duffey PL, DeVita VT Jr, Wiernik PH, Hubbard SM, Phares JC, et al.: Treatment of advanced-stage Hodgkin's disease: alternating noncrossresistant MOPP/CABS is not superior to MOPP. J Clin Oncol 1991,9:1409-1420.
106. Bartlett NL, Rosenberg SA, Hoppe RT, Hancock SL, Horning SJ: Brief chemotherapy, Stanford V, and adjuvant radiotherapy for bulky or advanced-stage Hodgkin's disease: a preliminary report. J Clin Oncol 1995, 13:1080-1088.
107. Horning SJ, Rosenberg SA, Hoppe RT: Brief chemotherapy (Stanford V) and adjuvant radiotherapy for bulky or advanced Hodgkin's disease: an update. Ann Oncol 1996, 7:105-108.
108. Glick JH, Young ML, Harrington D, Schlisky RL, Beck T, Neiman R, et al.: MOPP/ABV hybrid chemotherapy for advanced Hodgkin's disease significantly improves failure-free and overall survival: the 8-year results of the intergroup trial. J Clin Oncol 1998, 16:19-26.
109. Coleman M, Rafla S, Propert KJ, Glicksman A, Peterson B, Nissen N, et al.: Augmented therapy of extensive Hodgkin's disease: radiation to known disease or prolongation of induction chemotherapy did not improve survival-results of a Cancer and Leukemia Group B study. Int J Radiat Oncol Biol Phys 1998, 41:639-645. Augmenting six cycles of chemotherapy by either prolonging treatment (using 12 cycles), adding radiotherapy, or "sandwiching" radiotherapy into the chemotherapy regimen did not improve long-term survival, compared with using six cycles of chemotherapy alone.
110. Moreau P, Fleury J, Brice P, Colombat P, Boubdallah R, Lioure B, et al.: Early intensive therapy with autologous stem cell transplantation in advanced Hodgkin's disease: retrospective analysis of 158 cases from the French registry. Bone Marrow Transplant 1998, 21:787-793.
111. Moreau P, Milpied N, Rapp MJ, Moreau A, Bourdin S, Mahe MA, et al.: Early intensive therapy with autologous stem cell transplantation in high-risk Hodgkin's disease: long-term follow-up in 35 cases. Leuk Lymphoma 1998, 30:313-324.
112. Aviles A, Diaz-Maqueo JC, Talavera A, Nambo MJ, Garcia EL: Maintenance therapy with interferon alfa 2b in Hodgkin's disease. Leuk Lymphoma 1998, 30:651-656. Patients with advanced Hodgkin disease, who were in complete remission after induction chemotherapy, were randomly assigned to receive either one year of maintenance interferon therapy or no additional therapy. Patients randomized to interferon had improved duration of remission and an improved survival rate at seven years of therapy compared to patients randomized to no additional therapy.
113. Fisher RI, DeVita VT, Hubbard SM, Simon R, Young RC: Prolonged disease-free survival in Hodgkin's disease with MOPP reinduction after first relapse. Ann Intern Med 1979, 90:761-763.
114. Jagganath S, Armitage JO, Dicke KA, Tucker SL, Velasquez WS, Smith K, et al.: Prognostic factors for response and survival after high-dose cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation for relapsed Hodgkin's disease. J Clin Oncol 1989, 7:179-185.
115. Gribben JG, Linch DC, Singer CRJ, McMillan AK, Jarrett M, Goldstone AH: Successful treatment of refractory Hodgkin's disease by high-dose combination chemotherapy and autologous bone marrow transplantation. Blood 1989, 73:340-344.
116. Carella AM, Congiu AM, Gaozza E, Mazza P, Ricci P, Visani G, et al.: High-dose chemotherapy with autologous bone marrow transplantation in 50 advanced resistant Hodgkin's disease patients: an Italian study group report. J Clin Oncol 1988, 6:1411-1416.
117. Chopra R, McMillan AK, Linch DC, Yuklea S, Taghipour G, Pearce R, et al.: The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease. A single-center eight-year study of 155 patients. Blood 1993, 81:1137-1145.
118. Linch DC, Winfield D, Goldstone AH, Moir D, Hancock B, McMillan A, et al.: Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. Lancet 1993, 341:1051-1054.
119. Yuen AR, Rosenberg SA, Hoppe RT, Halpern JD, Homing SJ: Comparison between conventional salvage therapy and high-dose therapy with autografting for recurrent or refractory Hodgkin's disease. Blood 1997, 89:814-822.
120. Lancet JE, Rapoport AP, Brasacchio JF, Eberly S, Raubertas RF, Linder T, et al.: Autotransplantation for relapsed or refractory Hodgkin's disease: long-term follow-up and analysis of prognostic factors. Bone Marrow Transplant 1998, 22:265-271.
121. Arranz R, Tomas JF, Gil-Fernandez JJ, Martinez-Chamorro C, Granados E, Alegre A, et al.: Autologous stem cell transplantation (ASCT) for poor prognostic Hodgkin's disease: comparative results with two CBV regimens and importance of disease status at transplant. Bone Marrow Transplant 1998, 21:779-786.
122. Andre M, Henry-Amar M, Blaise D, Colombat P, Fleury J, Milpied N, et al.: Treatment-related deaths and second cancer risk after autologous stem-cell transplantation for Hodgkin's disease. Blood 1998, 92:1933-1940. A five-year cumulative incidence of second cancers of 8.9% was seen in patients receiving autologous transplants for Hodgkin's disease.
123. Renner C, Hartmann F, Pfreundschuh M: Treatment of refractory Hodgkin's disease with an anti-CD16/CD bispecific antibody. Cancer Immunol Immunother 1997, 45:184-186.
124. Ribrag V, Nasr F, Bouhris JH, Bosq J, Brault P, Girinsky T, et al.: VIP (etoposide, ifosfamide and cisplatinum) as a salvage intensification program in relapsed or refractory Hodgkin's disease. Bone Marrow Transplant 1998, 21:969-974.
125. Enblad G, Hagberg H, Gustavsson A, Glimelius B: Methyl-GAG, ifosfamide, methotrexate and etoposide (MIME) as salvage therapy for Hodgkin's disease: a prospective study. Eur J Haematol 1998, 60:166-171.
126. Little R, Wittes RE, Longo DL, Wilson WH: Vinblastine for recurrent Hodgkin's disease following autologous bone marrow transplant. J Clin Oncol 1998, 16:584-588.